Skip to main content

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Active, not recruiting · Phase 2 · NCT06614192

Conditions: Metastatic Colorectal Cancer

At a glance

Research payments reported, 2025
$1.6M
U.S. investigators named
37
Sites paid
35
Planned or actual enrollment
74

About the trial

Sponsor
AbbVie
Tested
Telisotuzumab Adizutecan (drug)
Dates
Started 2024-11-08; completion 2027-08
Results posted
Not yet

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab adizutecan in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms and each treatment arm receives a different dose of telisotuzumab adizutecan. Up to approximately 60 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study at approxim…

From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.6M in research payments for this study in 2025 (206 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.